Navigation Links
Osteoporosis Therapeutics - Pipeline Assessment and Market Forecasts to 2018
Date:10/25/2011

clusivity in 2008. The main treatment options available in the osteoporosis therapeutics market include alendronate, Reclast, Actonel, Boniva, Evista, Prolia, Forteo (teriparatide), Miacalcin (calcitonin salmon), Prempro (estrogen) and Premarin (conjugated estrogens and medroxyprogesterone acetate) among others.

Note: This is a on-demand report and will be delivered within 3 business days of the purchase (excluding weekends).

Scope

The report provides information on the key drivers and challenges of the osteoporosis therapeutics market. Its scope includes -

- Annualized seven key markets (the US, France, Germany, Italy, Spain, the UK and Japan) osteoporosis therapeutics market revenues data from 2005 to 2010, forecast for eight years to 2018.

- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes such as osteoclast activity inhibitors, osteoclast activity promoters, bone anabolic agents, SERMs, SARMs, RANKL inhibitors, dual acting bone agents, PTH release stimulator, cathepsin K inhibitor, bone morphogenetic protein signaler, aminobisphosphonate, DKK1 Protein inhibitor and osteoblast level promotor

- Analysis of the current and future competition in the seven key countries osteoporosis therapeutics market. Key market players covered are Amgen, Merck, Novartis, Pfizer, Osteologix, EffRx, Zydus, Astellas and Radius.

- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.

- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the osteoporosis therapeutics therapeutics market.

- Analysis of key recent licensing and partnership agreements in osteoporosis therapeutics ma
'/>"/>

SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. Zosano Pharma, Inc. and Asahi Kasei Pharma Corporation Enter Exclusive Licensing Agreement for a Weekly Transdermal Patch Formulation of Teribone™ (teriparatide acetate) for Osteoporosis
2. Womens Health Therapeutics, Analysis and Market Forecasts to 2016 - High Unmet Need will Drive the Uptake of Novel Drugs in the Menopause and Osteoporosis Markets
3. Tarsa Therapeutics Presents Positive Efficacy and Safety Data Comparing Its Oral Calcitonin to Nasal Calcitonin and Placebo in Phase III Osteoporosis Treatment Trial
4. Lilly Announces Review of Data on Long-Term Raloxifene Treatment for Postmenopausal Osteoporosis Published in Current Medical Research & Opinion
5. Radius, 3M Drug Delivery Systems Sign Development Agreement for Transdermal Delivery of BA058 for Treatment of Osteoporosis
6. Amgen and UCB Announce Positive Phase 2 Results of AMG 785/CDP7851 in Patients With Postmenopausal Osteoporosis (PMO)
7. Tarsa Therapeutics Reports Positive Top-Line Results From Pivotal Phase III ORACAL Trial of its Oral Calcitonin in Treatment of Postmenopausal Osteoporosis
8. ICAP Ocean Tomo Announces Patents for a New and Safer Method of Treatment of Osteoporosis and Tumor Metastasis Using a Novel Zoledronic Acid Combination
9. Commonly Prescribed Osteoporosis Drug Associated with Very Low Risk of Serious Jaw Disease
10. Tarsa Therapeutics Completes Phase III Trial of its Oral Calcitonin for Treatment of Postmenopausal Osteoporosis and Initiates Phase II Trial in Osteoporosis Prevention
11. $1,700,000 Funding of NeoStems Very Small Embryonic-Like Stem Cells Being Developed to Treat Osteoporosis Recommended by the Department of Defense Peer Reviewed Medical Research Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... , Dec. 22, 2014 Apnea Sciences ( ... offices in Aliso Viejo , California.  ... to the tremendous growth and worldwide expansion, a new ... patented SnoreRx, the anti snore cure have exceeded our ... "We are now in 23 countries and will ...
(Date:12/22/2014)... -- ConvaTec, a privately-held medical products and technologies company, today ... Executive Officer of the company, effective December 22, 2014. ... "The Board of Directors of ConvaTec thanks Mr. Berger ... three years," said Magnus Lundberg , the Chairman ... the company is well positioned for the future."  The ...
(Date:12/22/2014)...  Mark Farrah Associates (MFA), www.markfarrah.com , ... the 2015 marketplace exchange projections and insights about ... According to a recent ASPE (Office of the ... Health and Human Services) report, an estimated 6.7 ... through the Marketplace as of October 2014 and ...
Breaking Medicine Technology:ConvaTec Names Paul Moraviec Interim CEO Effective December 22, 2014 2Insights into the Marketplace and Individual Market Growth 2
... BRISBANE, Australia, April 14 Progen,Pharmaceuticals Limited (ASX: ... it,had presented new data on its patented PG500 ... Cancer Research (AACR) meeting being held,in San Diego. ... the world to discuss new and significant advances ...
... Satellite Symposium,3: The Challenges of Lung Transplantation ... of Heart and Lung Transplantation (ISHLT) Annual,Meeting ... some of,the unique challenges in achieving excellent ... A highlight of the session was the ...
Cached Medicine Technology:PG500 Series Presented at the AACR Annual Meeting in San Diego 2Lung Transplants in Cystic Fibrosis Patients With Life-Threatening Bacteria Sparks Debate at ISHLT Meeting 2Lung Transplants in Cystic Fibrosis Patients With Life-Threatening Bacteria Sparks Debate at ISHLT Meeting 3
(Date:12/25/2014)... Dennis Thompson HealthDay ... Very sick children with complex chronic illnesses can receive effective, ... "medical home," with easy access to a team of dedicated ... less likely to become seriously ill and need either hospitalization ... treatment at an enhanced medical home clinic at the University ...
(Date:12/25/2014)... common during the holidays, but there are strategies that can ... arrive at a party hungry. It may seem logical to ... party, but deprivation leads to hunger, and hunger leads to ... Mount Kisco, N.Y., said in a hospital news release. ... to have a snack before attending a party when you ...
(Date:12/25/2014)... By Dennis Thompson ... -- Researchers could be closing in on a "fountain of ... improve the health of older adults, a new study suggests. ... when given a drug that targets a genetic signaling pathway ... maker Novartis report. The experimental medication, a ...
(Date:12/25/2014)... New York (PRWEB) December 25, 2014 ... continue to move forward in a number of multidistrict ... of West Virginia, Bernstein Liebhard LLP reports. According to ... is scheduled to convene a Joint Status Conference in ... 10:00 a.m. Parties have been directed to submit a ...
(Date:12/25/2014)... 2014 Plugin creators from Pixel Film ... fully customizable business presentation tool made specifically for ... 5k business tool, users can now display their stats ... Pixel Film Studios. “ProFire 5k gives users a multiple ... professionalism to a presentation” , Pixel Film Studios takes ...
Breaking Medicine News(10 mins):Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 2Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 3Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 2Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 3Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 3Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 4Health News:Announcing a new ProFire 5k plugin from Pixel Film Studios for Final Cut Pro X Professionals 2
... Smithsonian Whistleblower and Asbestos Experts to Dispute Smithsonian,s ... Safe for Workers and Public WASHINGTON, March 16 ... press conference on Tuesday, March 17, to announce ... the U.S. Office of Special Counsel. In ...
... Inc. (NYSE: WLP ) has placed No. ... Diversity(R) list, which was announced last week by DiversityInc.A ... from last year, vied for the honor this year, ... companies. "In its fourth year participating, WellPoint demonstrates the ...
... Children,s National Medical Center and colleagues in Tokyo publish results, video ... , ... Washington, DC (PRWEB) March 16, 2009 -- Genetic ... Center of Neurology and Psychiatry in Tokyo published the results of ...
... maintain a healthy weight and who have lower perceived ... associated with aging than obese and stressed women, according ... Sister Study. The long-term Sister Study is looking at ... had breast cancer to identify factors associated with developing ...
... Uninsured, including those who are recently unemployed, can attend ... expertPITTSBURGH, March 16 As the nation marks National ... Highmark is offering resources to help Pennsylvanians without health ... the Pennsylvania Insurance Department found that the uninsured ranks ...
... key, however, experts say, , , MONDAY, March 16 (HealthDay ... and tools have significantly improved the management of this ... in the mid-,90s, children with severe asthma during 2004 ... and rescue inhalers, and their lung function scores were ...
Cached Medicine News:Health News:Smithsonian Worker Exposed to Asbestos Files Whistleblower Retaliation Complaint 2Health News:WellPoint Named to DiversityInc's '2009 DiversityInc Top 50 Companies for Diversity'(R) 2Health News:WellPoint Named to DiversityInc's '2009 DiversityInc Top 50 Companies for Diversity'(R) 3Health News:WellPoint Named to DiversityInc's '2009 DiversityInc Top 50 Companies for Diversity'(R) 4Health News:First Treatment for Muscular Dystrophy in Sight: Scientists Harness Exon-Skipping in Large Animal to Successfully Treat Duchenne Muscular Dystrophy 2Health News:First Treatment for Muscular Dystrophy in Sight: Scientists Harness Exon-Skipping in Large Animal to Successfully Treat Duchenne Muscular Dystrophy 3Health News:First Treatment for Muscular Dystrophy in Sight: Scientists Harness Exon-Skipping in Large Animal to Successfully Treat Duchenne Muscular Dystrophy 4Health News:First Treatment for Muscular Dystrophy in Sight: Scientists Harness Exon-Skipping in Large Animal to Successfully Treat Duchenne Muscular Dystrophy 5Health News:First sister study results reinforce the importance of healthy living 2Health News:First sister study results reinforce the importance of healthy living 3Health News:Highmark Offers Resources to Help Pennsylvanians Without Health Insurance During Cover the Uninsured Week 2Health News:Highmark Offers Resources to Help Pennsylvanians Without Health Insurance During Cover the Uninsured Week 3Health News:New Treatments Improve Control for Severe Asthma 2Health News:New Treatments Improve Control for Severe Asthma 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: